Published in PLoS One on September 21, 2012
Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep (2015) 0.94
Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol (2015) 0.88
Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study. Medicine (Baltimore) (2015) 0.81
Current challenges and the management of chronic hepatitis C in mainland China. J Clin Gastroenterol (2014) 0.81
Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J (2015) 0.81
Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients. J Biomed Res (2014) 0.78
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal. PLoS One (2015) 0.77
Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms. World J Gastroenterol (2014) 0.75
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
The global burden of hepatitis C. Liver Int (2009) 8.89
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology (2010) 3.26
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther (2011) 3.10
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology (2008) 2.70
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology (2009) 2.33
Interferon-lambda serum levels in hepatitis C. J Hepatol (2010) 2.28
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology (2011) 2.03
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut (2010) 1.85
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol (2010) 1.80
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology (2011) 1.68
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2010) 1.58
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology (2011) 1.55
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol (2011) 1.47
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol (2011) 1.45
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology (2011) 1.43
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One (2011) 1.39
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology (2012) 1.26
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol (2010) 1.19
Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther (2011) 1.18
IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One (2010) 1.17
Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol (2011) 1.13
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol (2011) 1.12
A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur J Gastroenterol Hepatol (2011) 1.12
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat (2011) 1.10
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis (2011) 1.08
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One (2011) 1.04
Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology (2011) 1.02
Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol (2011) 1.00
IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population. AIDS Res Hum Retroviruses (2011) 0.95
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology (2011) 0.94
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol (2011) 0.94
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS (2011) 0.93
Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data. J Gastroenterol Hepatol (2012) 0.91
Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol (2011) 0.87
Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. Antivir Ther (2011) 0.86
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse. AIDS (2011) 0.83
Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Liver Int (2011) 0.80
Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin. Hepatol Res (2011) 0.79
Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C. J Med Virol (2011) 0.78
Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias? Hepatology (2011) 0.76
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res (2007) 3.85
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol (2012) 2.63
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 2.62
Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol (2011) 2.43
Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. J Clin Oncol (2014) 2.42
Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys (2012) 2.17
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology (2008) 2.13
Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol (2010) 2.09
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum (2012) 2.03
E-cadherin-mediated cell-cell contact is critical for induced pluripotent stem cell generation. Stem Cells (2010) 1.97
Molecular evidence for spread of two major methicillin-resistant Staphylococcus aureus clones with a unique geographic distribution in Chinese hospitals. Antimicrob Agents Chemother (2008) 1.91
Complications After Mastectomy and Immediate Breast Reconstruction for Breast Cancer: A Claims-Based Analysis. Ann Surg (2016) 1.86
Automatically generating gene summaries from biomedical literature. Pac Symp Biocomput (2006) 1.83
miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta. Genes Dev (2010) 1.80
Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int (2011) 1.70
Transcriptome sequencing and de novo analysis for Ma bamboo (Dendrocalamus latiflorus Munro) using the Illumina platform. PLoS One (2012) 1.51
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem (2009) 1.50
Complex threshold method for identifying pixels that contain predominantly noise in magnetic resonance images. J Magn Reson Imaging (2008) 1.47
Removing background phase variations in susceptibility-weighted imaging using a fast, forward-field calculation. J Magn Reson Imaging (2009) 1.39
Reprogramming of mouse and human somatic cells by high-performance engineered factors. EMBO Rep (2011) 1.38
Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis. Mol Immunol (2011) 1.35
Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos (2011) 1.35
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int (2011) 1.30
Structure and mechanism of the uracil transporter UraA. Nature (2011) 1.29
ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell Signal (2008) 1.27
IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One (2012) 1.25
Characterization of full-length enterovirus 71 strains from severe and mild disease patients in northeastern China. PLoS One (2012) 1.24
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol (2014) 1.23
Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res (2008) 1.21
Start codon targeted polymorphism for evaluation of functional genetic variation and relationships in cultivated peanut (Arachis hypogaea L.) genotypes. Mol Biol Rep (2010) 1.19
Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm (2010) 1.17
Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology (2008) 1.17
Multiple interferon stimulated genes synergize with the zinc finger antiviral protein to mediate anti-alphavirus activity. PLoS One (2012) 1.16
Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China. Int J Med Sci (2011) 1.15
Molecular mechanism of photoactivation and structural location of the cyanobacterial orange carotenoid protein. Biochemistry (2013) 1.13
DNA methylation-dependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target. Cancer Res (2010) 1.12
Stk40 links the pluripotency factor Oct4 to the Erk/MAPK pathway and controls extraembryonic endoderm differentiation. Proc Natl Acad Sci U S A (2010) 1.12
New algorithm for quantifying vascular changes in dynamic contrast-enhanced MRI independent of absolute T1 values. Magn Reson Med (2007) 1.10
Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer (2013) 1.07
Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol Endocrinol (2003) 1.05
Physical and functional interaction of growth hormone and insulin-like growth factor-I signaling elements. Mol Endocrinol (2004) 1.04
More synergetic cooperation of Yamanaka factors in induced pluripotent stem cells than in embryonic stem cells. Cell Res (2009) 1.04
CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res (2009) 1.04
Metalloprotease-mediated GH receptor proteolysis and GHBP shedding. Determination of extracellular domain stem region cleavage site. J Biol Chem (2002) 1.03
Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B. J Interferon Cytokine Res (2012) 1.01
Germline-competent mouse-induced pluripotent stem cell lines generated on human fibroblasts without exogenous leukemia inhibitory factor. PLoS One (2009) 1.01
Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling. J Biol Chem (2003) 1.00
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med (2009) 1.00
Genetic polymorphisms of glutathione S-transferase genes and susceptibility to colorectal cancer: a case-control study in an Indian population. Cancer Epidemiol (2010) 1.00
Determinants of growth hormone receptor down-regulation. Mol Endocrinol (2007) 1.00
Endotoxin-induced proteolytic reduction in hepatic growth hormone (GH) receptor: a novel mechanism for GH insensitivity. Mol Endocrinol (2008) 0.99
Deletion of IGF-I receptor (IGF-IR) in primary osteoblasts reduces GH-induced STAT5 signaling. Mol Endocrinol (2010) 0.99
A fast workflow for identification and quantification of proteomes. Mol Cell Proteomics (2013) 0.98
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology (2014) 0.98
Janus kinase 2 enhances the stability of the mature growth hormone receptor. Endocrinology (2005) 0.98
Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Mol Endocrinol (2007) 0.98
Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol Endocrinol (2011) 0.96
Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med (2014) 0.95
Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis C. Mediators Inflamm (2012) 0.95
Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Arch Neurol (2012) 0.95
Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage. J Biol Chem (2005) 0.95
Different developmental potential of pluripotent stem cells generated by different reprogramming strategies. J Mol Cell Biol (2011) 0.95
High-efficiency somatic reprogramming induced by intact MII oocytes. Cell Res (2010) 0.95
Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries. Int J Radiat Oncol Biol Phys (2013) 0.95
Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatography-mass spectrometry. J Proteome Res (2012) 0.94
Effectiveness of radiation for prevention of mastectomy in older breast cancer patients treated with conservative surgery. Cancer (2012) 0.94
Expression profiling of salinity-alkali stress responses by large-scale expressed sequence tag analysis in Tamarix hispid. Plant Mol Biol (2007) 0.94
Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies. Cell Mol Immunol (2010) 0.94
Caveolar and lipid raft localization of the growth hormone receptor and its signaling elements: impact on growth hormone signaling. J Biol Chem (2004) 0.94
Irreversible electroporation: an in vivo study with dorsal skin fold chamber. Ann Biomed Eng (2012) 0.93
Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering. Mol Endocrinol (2007) 0.93
Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther (2007) 0.93
Loss of N-cadherin and alpha-catenin in the proximal tubules of aging male Fischer 344 rats. Mech Ageing Dev (2004) 0.93
Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis. Cancer Res (2007) 0.92
Serum pepsinogen II is a better diagnostic marker in gastric cancer. World J Gastroenterol (2012) 0.92
Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. Cancer Sci (2003) 0.92
ROCK pathway participates in the processes that 15-hydroxyeicosatetraenoic acid (15-HETE) mediated the pulmonary vascular remodeling induced by hypoxia in rat. J Cell Physiol (2010) 0.92
Janus kinase 2 influences growth hormone receptor metalloproteolysis. Endocrinology (2006) 0.91
Abrogation of ER stress-induced apoptosis of alveolar epithelial cells by angiotensin 1-7. Am J Physiol Lung Cell Mol Physiol (2013) 0.91
Protein predictive signatures for lymph node metastasis of gastric cancer. Int J Cancer (2012) 0.90
Association of mycobacterial antigen-specific CD4(+) memory T cell subsets with outcome of pulmonary tuberculosis. J Infect (2009) 0.90
Growth hormone alters epidermal growth factor receptor binding affinity via activation of extracellular signal-regulated kinases in 3T3-F442A cells. Endocrinology (2004) 0.90
Elevated expression of Tim-3 on CD8 T cells correlates with disease severity of pulmonary tuberculosis. J Infect (2011) 0.89
Diagnostic performance of multiplex cytokine and chemokine assay for tuberculosis. Tuberculosis (Edinb) (2012) 0.89
A myeloid cell population induced by Freund adjuvant suppresses T-cell-mediated antitumor immunity. J Immunother (2010) 0.89
Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer (2011) 0.89
Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach. Am J Pathol (2011) 0.89
The salt-responsive transcriptome of Populus simonii × Populus nigra via DGE. Gene (2012) 0.89
Polymorphisms in DNA repair genes XRCC1, XRCC3 and XPD, and colorectal cancer risk: a case-control study in an Indian population. J Cancer Res Clin Oncol (2010) 0.88
Signaling profiling at the single-cell level identifies a distinct signaling signature in murine hematopoietic stem cells. Stem Cells (2012) 0.88
Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology (2014) 0.88
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PLoS One (2010) 0.88
miR-154 targeting ZEB2 in hepatocellular carcinoma functions as a potential tumor suppressor. Oncol Rep (2015) 0.88
Lnk deficiency partially mitigates hematopoietic stem cell aging. Aging Cell (2012) 0.87
Identification of expressed sequence tags in an alkali grass (Puccinellia tenuiflora) cDNA library. J Plant Physiol (2006) 0.87
Identification of genes responsive to salt stress on Tamarix hispida roots. Gene (2008) 0.87